全球足底筋膜炎治疗市场-2022-2029

市场概况

在预测期间（2022-2029 年），足底筋膜炎治疗市场预计将以 4.2% 的复合年增长率增长。

足底筋膜炎是足底筋膜的炎症，足底筋膜是支撑足底足弓的纤维组织带。当该组织带超载或拉伸时会发生这种情况。小撕裂，尤其是筋膜与跟骨相交处。足底筋膜炎在肥胖人群和孕妇中很常见，超重会使脆弱的足底筋膜超负荷。它在糖尿病患者中也很常见，但确切原因尚不清楚。

市场动态

预计足底筋膜炎患者数量的增加将推动预测期内足底筋膜炎治疗市场的增长。

矫形技术的日益普及以及足底筋膜炎患者的增加是全球市场增长的主要驱动力之一。根据美国国家卫生统计中心 (NCHS) 的数据，估计全世界每年约有 200 万人患有足底筋膜炎。走路姿势不当、运动量突然增加、长时间站立、负重、鞋子不合脚等都会诱发足底筋膜微撕裂，导致足底筋膜炎。

此外，肥胖的增加也有望推动足底筋膜炎治疗市场的增长。

老年人和肥胖的人更容易患足底筋膜炎。足底筋膜炎会导致足底筋膜（连接足跟和脚趾骨的组织）变得僵硬且更具抑制性，从而导致剧烈疼痛和其他并发症。

根据世界卫生组织 (WHO) 的数据，2016 年有超过 19 亿 18 岁以上的成年人超重。其中，超过 6.5 亿人肥胖。2016 年，39% 的 18 岁以上成年人超重，13% 肥胖。世界上大多数人口生活在超重和肥胖造成的死亡人数多于体重不足死亡人数的国家。2019 年，有 3800 万五岁以下儿童被发现超重或肥胖。2016 年，超过 3.4 亿 5-19 岁的儿童和青少年超重或肥胖。

久坐不动的生活方式的增加以及饮食习惯的改变导致肥胖增加，这会对关节和脚踝造成压力并导致足底筋膜炎。

高治疗成本阻碍市场增长

然而，高昂的治疗费用和对足底筋膜炎的低认识正在阻碍市场增长。市场增长预计也将受到製造有效治疗医疗设备所需原材料价格波动的阻碍。此外，也有人担心製造商库存和原材料大，产品盈利能力下降，这可能会限制市场增长。

流行病学

足底筋膜炎在美国非常普遍，据说每年有数百万人经历足跟痛。足底筋膜炎可由多种原因引起，但大多数情况下是由过度使用造成的压力引起的。据估计，每年有超过 200 万美国人接受足底足跟痛的治疗。现役军人和文职僱员中的流行率特别高。在全球范围内，报告的足底筋膜炎发病率在运动员和非运动员中均约为 10%。

足底近端筋膜炎患者的平均年龄约为 45 岁。还有一个已知的性别差异，近端足底筋膜炎在女性中的发生率是男性的两倍。

足底筋膜炎约占跑步者相关损伤的 10%，占所有需要专科护理的足部疾病的 11% 至 15%。大约 10% 的普通人群受到影响，其中 83% 是年龄在 25 至 65 岁之间的在职工作成年人。

市场细分

按治疗类型，全球市场分为药物疗法、支具疗法、衝击波疗法、手术等。

矫形器部分在预测期内主导全球足底筋膜炎治疗市场

支具是一种支具，用于在行走或跑步时支撑虚弱的肌肉。这些装置还可以提高舒适度并减缓挛缩的进展。这些可以在白天或晚上的任何时间佩戴。牙套的使用取决于患者问题的类型。常见的支具包括膝踝支具和踝足支具。

足底筋膜炎通常是由扁平足引起的，这使得它们看起来更大。更换足弓结构是减轻足部负担的有效方法之一。对于那些患有足底筋膜炎不适的人来说，支具可能是一个有价值的解决方案。因此，为了满足消费者的需求，市场参与者正专注于开发各种新型和技术先进的矫形器，这些矫形器有望推动整个市场。

在预测期内，治疗型冲击波治疗部分预计将以最快的复合年增长率增长。

衝击波疗法市场分为体外衝击波疗法和内部气动衝击波疗法。足底筋膜炎是一种日益常见的足部疼痛疾病，并且在全球范围内进行越来越多的治疗。体外衝击波疗法将声波引导到脚后跟的疼痛区域以促进癒合。它通常用于对保守治疗无反应的慢性足底筋膜炎。一些研究显示了有希望的结果，但它们并非始终有效。

预计药物治疗在预测期内将显着增长

药物治疗很有帮助，因为它最初会加重疼痛，尤其是当患者开始进行伸展运动时。

用于治疗足底筋膜炎的药物包括：

镇痛剂：镇痛剂可确保患者舒适，促进肺部如厕，具有镇静作用，对创伤和受伤患者有效。

对乙□氨基酚（不含阿司匹林的 Anacin、Feverall、Tylenol）可有效缓解轻度至中度的急性疼痛。然而，它没有外周抗炎活性。

非甾体抗炎药。非甾体抗炎药具有镇痛和解热作用。它抑制其白三烯合成、溶□体□释放、脂氧合□活性、中性粒细胞聚集和各种细胞膜功能。

布洛芬（Advil、Excedrin IB、Motrin、Ibuprin）用于轻度至中度疼痛的患者。它通过减少前列腺素的合成来抑制炎症反应和疼痛。

酮洛芬（Actron、Orudis、Oruvail）：用于缓解轻度至中度疼痛和炎症。小型、老年人和患有肾臟或肝臟疾病的人适用于初始低剂量给药。

□普生（Aleve、Anaprox、Naprelan、Naprosyn）：轻度至中度疼痛缓解；通过降低负责前列腺素合成的环氧合□的活性来抑制炎症反应和疼痛。非甾体抗炎药可降低肾小球内压力并减少蛋白尿。

按最终用户划分，它分为医院、门诊手术中心、诊所等。

医院主导全球足底筋膜炎药物市场

由于在医院进行的外科手术数量不断增加，医院部门在 2019 年的收入方面占市场的主要份额。药物疗法越来越受到关注，因为它是治疗足底筋膜炎相关症状（如炎症和疼痛）最广泛采用的治疗方法。然而，很少有人需要手术将足底筋膜与跟骨分开。通常仅在疼痛严重且其他治疗失败时才选择手术。手术通过开放手术或局部麻醉下的小切口进行。

地理特征

足底筋膜炎治疗将在 2021 年占据北美最大的市场份额，增加对开发新治疗方案的投资、大量患有足痛疾病的人口基数以及不断扩大的分销网络。预计在预测期内将显着增长.在美国，足底筋膜炎的患病率正在迅速增加。例如，美国足病医学协会 (APMA) 的一项调查显示，77% 的美国人患有足部疼痛。这意味着美国约有 200 万人患有足底筋膜炎，这是最常见的足部疼痛类型之一。此外，美国肥胖症的增加和生活方式的改变正在推动市场的增长。根据国家临床试验 (NCT) 登记处的数据，截至 2020 年 6 月 18 日，美国正在招募大约六项不同发展阶段的临床试验，用于治疗足底筋膜炎。

竞争格局

世界市场得到巩固。几家新兴市场公司专注于开发价格合理且易于使用的新产品并将其推向市场。例如，2021 年 9 月 28 日，FDA 批准了衝击波疗法治疗足底筋膜炎。衝击波疗法有两种类型：聚焦衝击波和辐射压力波。

足底筋膜炎治疗市场竞争适度，由几个主要参与者组成。为市场增长做出贡献的主要参与者包括A.Algeo Limited、Superfeet Worldwide, Inc.、Hanger, Inc.、Bayer Group（□）、GlaxoSmithKline Plc、Bauerfeind AG、Pfizer, Inc、Sanofi、Ottobock SE &Co.、KGaA.（Ottobock Holding）等

领先的公司正在采取多种增长战略，例如产品发布、收购和合作伙伴关係，这有助于全球市场的增长。例如：

产品发布 2021 年 8 月 24 日，Superfeet Worldwide LLC 推出了 ADAPT run 系列鞋垫。该系列已获得自适应舒适技术的专利。这些跑步鞋垫有两种足弓高度可供选择。ADAPT Run 是细低足弓，而 ADAPT Run Max 是深跟杯和高足弓。

Pfizer Inc.

概述

Pfizer Inc.是世界领先的创新生物製药公司之一，每年发现、开发和提供 170 多种药物和疫苗保健产品，改善英国和世界各地数百万人的生活。

产品介绍

DEPO-MEDRONE(R) (METHYLPREDNISOLONE ACETATE) Depot-medron 含有醋酸甲基强的松龙。甲基强的松龙属于一组称为皮质类固醇或类固醇的药物。肾上腺皮质类固醇是您体内自然产生的，对许多身体功能都很重要。

目录

第一章 调查方法和范围

• 调查方法
• 调查目的和范围

第二章市场定义和概述

第三章执行摘要

• 按治疗类型划分的市场细分
• 最终用户的市场细分
• 区域市场细分

第四章市场动态

• 市场影响因素
  • 促进者
    • 开发先进的足底筋膜炎治疗产品和解决方案
    • 随着肥胖症的增加，足底筋膜炎病例不断增加
  • 抑製剂
    • 治疗费用高
  • 商机
  • 影响分析

第五章行业分析

• 流行病学
• 管道分析
• 波特五力分析
• 供应链分析
• 临床试验
• 定价分析
• 法律法规分析
• 保险报销分析
• 未满足的需求

第 6 章 COVID-19 分析

• COVID-19 的市场分析
  • COVID-19 之前的市场情景
  • COVID-19 的当前市场情景
  • COVID-19 后或未来情景
• COVID-19 中的价格动态
• 供需谱
• 大流行期间与市场相关的政府努力
• 製造商的战略举措
• 概括

第 7 章 按治疗类型

• 手术
• 衝击波疗法
  • 体外衝击波疗法（ESWT）
  • 体外气动衝击波治疗 (IPST)
• 药物治疗
  • 止痛药
  • 对乙□氨基酚（阿司匹林、游离Anacin、Feverall、Tylenol）等。
  • 非甾体抗炎药（NSAIDs）
  • 布洛芬（Advil、Excedrin IB、Motrin、布普林）
  • 酮洛芬（Actron、Orudis、Oruveil）
  • □普生（Aleve、Anaprox、Naplelan、Naprosyn）
  • 其他
• 支撑
• 其他治疗剂

第 8 章最终用户

• 医院
• 骨科诊所
• 其他

第9章按地区

• 北美
  • 美国
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 意大利
  • 西班牙
  • 欧洲其他地区
• 南美洲
  • 巴西
  • 阿根廷
  • 其他南美地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
• 中东/非洲

第 10 章 竞争格局

• 竞争情景
• 市场/份额分析
• 併购分析

第十一章公司简介

• Pfizer, Inc.
  • 公司简介
  • 产品组合和描述
  • 主要亮点
  • 财务摘要
• Shapecrunch Technology Pvt Ltd
• Hanger, Inc.
• A. Algeo Limited
• Bauerfeind AG
• Ottobock SE & Co. KGaA（Ottobock Holding）
• GlaxoSmithKline plc
• Sanofi
• Bayer Group（Dr. Scholl's）
• Superfeet Worldwide, Inc.（*LIST NOT EXHAUSTIVE）

第 12 章 重要注意事项

第 13 章 数据管理

Market Overview

The Plantar Fasciitis Treatment Market is expected to grow at a high CAGR of 4.2% during the forecasting period (2022-2029).

Plantar fasciitis is an inflammation of the plantar fascia which is a fibrous band of tissue on the bottom of the foot which supports the arch. It occurs when this band of tissue is overloaded or overstretched. This causes small tears in the fibers of the fascia, especially where the fascia meets the heel bone. Plantar fasciitis is common in obese people and pregnant women, their extra body weight overloads the delicate plantar fascia. It is also common in people with diabetes, although the exact reason for this is unknown.

Market Dynamics

The increasing number of plantar fasciitis cases is expected to drive the plantar fasciitis treatment market growth over the forecast period

Increasing adoption of orthotics techniques coupled with rising cases of plantar fasciitis is among the major factors driving the market growth globally. As per the National Center for Health Statistics (NCHS), it is estimated that about two million population suffers from plantar fasciitis annually worldwide. Incorrect walking posture, a sudden rise in sports activities, prolonged standing, weight-bearing, ill-fitted shoes can trigger micro-tears in the plantar fascia, and result in plantar fasciitis.

Increasing incidences of obesity are also expected to drive plantar fasciitis treatment market growth

Geriatric. and obese people are more prone to plantar fasciitis. It leads to sharp pain and other complications, in which, plantar fascia, a tissue connecting the heel and the toe bones becomes less flexible and more constrained.

As per the World Health Organization (WHO), in 2016, more than 1.9 billion adults, 18 years and older, were overweight. Of these over 650 million were obese. 39% of adults aged 18 years and over were overweight in 2016, and 13% were obese. Most of the world's population live in countries where overweight and obesity kill more people than underweight. Thirty-eight million children under the age of 5 were overweight or obese in 2019. Over 340 million children and adolescents aged 5-19 were overweight or obese in 2016.

An increase in the number of individuals living sedentary lifestyles along with changes in eating habits leads to a rise in obesity, which puts pressure on the joints and ankles and can result in plantar fasciitis.

The high cost of treatment is hampering the market growth

However, the high cost of the treatment and lack of awareness about the plantar fasciitis condition is hampering the growth of the market. Also, the lack of stable raw materials pricing for the production of effective therapeutic medical devices is expected to hinder the growth of the market. Some concerns regarding the decline in profitability ratio for the products amid the availability of large inventory and raw material stock with the manufacturers are expected to restrict the market growth.

Epidemiology

Plantar fasciitis is very common in the US, with millions experiencing heel pain every year. The cause of plantar fasciitis is multifactorial, but most cases result from overuse stress. It is estimated that over two million Americans seek treatment for plantar heel pain each year. The prevalence of active and military populations is especially high. Globally, in both athletic and nonathletic populations, the incidence of plantar fasciitis is reported to be approximately 10%.

The average age of a patient with proximal plantar fasciitis is around 45 years. There is also known sex-based dimorphism in presentation, with proximal plantar fasciitis being twice as common in women as in men.

Plantar fasciitis accounts for about 10% of runner-related injuries and 11% to 15% of all foot symptoms requiring professional medical care. It occurs in about 10% of the general population as well, with 83% of these patients being active working adults between the ages of 25 and 65 years old.

Market Segmentation:

By treatment type, the global market is classified into medication therapy, orthotics, shockwave therapy, surgery, and others.

The orthotic devices segment is dominating the global plantar fasciitis treatment market over the forecast period

Orthotic devices, also known as orthoses, are the type of braces that supports weakened muscles while walking or running. These devices also improve comfort and slow down the progress of contractures. These can be worn at any time of the day or night. The use of an orthotic device depends on the patient's type of concern. The common types of orthotic devices include knee-ankle-foot orthoses and ankle-foot orthoses.

Plantar fasciitis commonly occurs as a result of flattening of the foot, which makes the foot appear larger. One of the best ways to ease the burden on the foot is by essentially replacing the structure of the arch. Orthotics are a valuable solution for people struggling with the discomfort of plantar fasciitis. Hence, to reach consumer requirements, market players are focusing on developing different novel and technologically advanced orthotic devices which are anticipated to propel the overall market.

The Shockwave therapy segment of treatment type is expected to grow at the fastest CAGR over the forecast period

The shockwave therapy market is segmented into extracorporeal shock wave therapy and intracorporeal pneumatic shockwave therapy. Plantar fasciitis is growing due to increasing common foot pain conditions which has also raised the number of treatments globally. In Extracorporeal shock wave therapy, sound waves are directed at the area of heel pain to stimulate healing. It is commonly used for chronic plantar fasciitis that hasn't responded to more-conservative treatments. Some studies show promising results, but it isn't consistently effective.

Medication therapy is expected to grow significantly over the forecast period

Medication is useful in the early stages, especially if the patient has begun stretching exercises, because, initially, these can worsen the pain.

Some of the medications used for the treatment of plantar fasciitis are:

Analgesics: Analgesics ensure patient comfort, promote pulmonary toilet, and have sedating properties, which are beneficial for patients who have sustained trauma or who have sustained injuries.

Acetaminophen (Aspirin Free Anacin, Fever all, Tylenol) is effective in relieving mild to moderate acute pain; however, it has no peripheral anti-inflammatory effects.

Nonsteroidal Anti-inflammatory Drugs: NSAIDs have analgesic and antipyretic activities. They inhibit its leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell membrane functions.

Ibuprofen (Advil, Excedrin IB, Motrin, Ibuprin) are used for patients with mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis.

Ketoprofen (Actron, Orudis, Oruvail): For the relief of mild to moderate pain and inflammation. Small initial dosages are indicated in small and elderly patients and those with renal or liver disease.

Naproxen (Aleve, Anaprox, Naprelan, Naprosyn): For the relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing the activity of cyclooxygenase, which is responsible for prostaglandin synthesis. NSAIDs decrease intraglomerular pressure and decrease proteinuria.

By end-user, the market is segmented into hospitals, ambulatory surgical centers, clinics, and others.

Hospitals are contributing to the majority of the market share in the global market for plantar fasciitis treatment

The hospital's segment held the major share of the market in terms of revenue in 2019 due to the rising number of surgeries for treatment, which takes place in hospitals. Medication therapy has gained traction due to the most widely adopted line of therapy to manage symptoms related to plantar fasciitis like inflammation and pain. However, few people need surgery to detach the plantar fascia from the heel bone. Surgery is generally an option only when the pain is severe, and other treatments have failed. It can be done as an open procedure or through a small incision with local anesthesia.

Geographical Presentation:

North America holds plantar fasciitis treatment accounted for the largest market share in 2021, and is expected to grow significantly over the forecast period, due to increasing investments in the development of new treatment options, large population base with foot pain conditions, and expansion in the distribution networks. The prevalence rates of plantar fasciitis are growing rapidly in the United States. For instance, as per the American Podiatric Medical Association (APMA), research study revealed that 77 percent of Americans suffer from the foot pain. It is Approximately 2 million people in the United States will suffer from Plantar Fasciitis, one of the most common foot pains. Also, the rise in the number of obese people in the United States and changing lifestyle is driving the growth of the market. As per the National Clinical Trials (NCT) registry, as of June 18, 2020, currently, there are about 6 recruiting clinical trials across different phases of development for the treatment of Plantar Fasciitis in the United States.

Competitive Landscape:

The global market is consolidated. Several private companies are focusing on the development and introduction of novel products into the market, which are easily affordable and accessible. For instance, on 28th September 2021, the FDA approved Shock wave therapy treatment for plantar fasciitis. There are two types of shock wave therapies: focused shock waves and radial pressure waves.

The plantar fasciitis treatments market is moderately competitive and consists of several major players. Some of the key players which are contributing to the growth of the market include A. Algeo Limited, Superfeet Worldwide, Inc., Hanger, Inc., Bayer Group (Dr. Scholl's), GlaxoSmithKline Plc, Bauerfeind AG, Pfizer, Inc., Sanofi, and Ottobock SE & Co., KGaA. (Ottobock Holding), among others.

The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance,

Product Launch: On 24th August 2021, Superfeet Worldwide LLC launched ADAPT run collection of insoles. This collection is patented under Adaptive Comfort Technology. These running insoles are available in two arch heights: ADAPT Run with a thinner profile and lower arch and ADAPT Run Max with a deeper heel cup and higher arch profile.

Pfizer, Inc.

Overview:

Pfizer is one of the world's premier innovative biopharmaceutical companies, discovering, developing, and providing over 170 different medicines and vaccines healthcare products to help improve the lives of millions of people in the UK and around the world every year.

Product Portfolio:

DEPO-MEDRONE® (METHYLPREDNISOLONE ACETATE) Depo-Medrone contains methylprednisolone acetate. Methylprednisolone belongs to a group of medicines called corticosteroids or steroids. Corticosteroids are produced naturally in your body and are important for many body functions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Treatment Type
• 3.2. Market Snippet by End-User
• 3.3. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Development of technically advanced products and solutions for treatment of plantar fasciitis
    • 4.1.1.2. Rising cases of plantar fasciitis couple with increasing obesity
    • 4.1.1.3. XX
  • 4.1.2. Restraints:
    • 4.1.2.1. High cost of treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Epidemiology
• 5.2. Pipeline Analysis
• 5.3. Porter's Five Forces Analysis
• 5.4. Supply Chain Analysis
• 5.5. Clinical Trials
• 5.6. Pricing Analysis
• 5.7. Regulatory Analysis
• 5.8. Reimbursement Analysis
• 5.9. Unmet Needs

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Treatment Type

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type Segment
• 7.3. Market Attractiveness Index, By Treatment Type Segment
  • 7.3.1. Surgery*
    • 7.3.1.1. Introduction
    • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3.2. Shockwave Therapy
    • 7.3.2.1. Extracorporeal Shock Wave Therapy (ESWT)
    • 7.3.2.2. Intracorporeal Pneumatic Shockwave Therapy (IPST)
  • 7.3.3. Medication Therapy
    • 7.3.3.1. Analgesics
    • 7.3.3.1.1. Acetaminophen (Aspirin Free Anacin, Feverall, Tylenol)
    • 7.3.3.2. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
    • 7.3.3.2.1. Ibuprofen (Advil, Excedrin IB, Motrin, Ibuprin)
    • 7.3.3.2.2. Ketoprofen (Actron, Orudis, Oruvail)
    • 7.3.3.2.3. Naproxen (Aleve, Anaprox, Naprelan, Naprosyn)
    • 7.3.3.3. Others
  • 7.3.4. Orthotics
  • 7.3.5. Other treatments

8. By End-User

• 8.1. Introduction
• 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment
• 8.3. Market Attractiveness Index, By End-User Segment
  • 8.3.1. Hospitals*
    • 8.3.1.1. Introduction
    • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3.2. Orthopedic Clinics
  • 8.3.3. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. U.K.
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
  • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment Type
  • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Pfizer, Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Key Highlights
  • 11.1.4. Financial Overview
• 11.2. Shapecrunch Technology Pvt Ltd
• 11.3. Hanger, Inc.
• 11.4. A. Algeo Limited
• 11.5. Bauerfeind AG
• 11.6. Ottobock SE & Co. KGaA (Ottobock Holding)
• 11.7. GlaxoSmithKline plc
• 11.8. Sanofi
• 11.9. Bayer Group (Dr. Scholl's)
• 11.10. Superfeet Worldwide, Inc.(*LIST NOT EXHAUSTIVE)

12. Premium Insights

13. DataM Intelligence

• 13.1. Appendix
• 13.2. About Us and Services
• 13.3. Contact Us